The Indigo System in Acute Lower Limb Malperfusion

Study Overview
=================
Brief Summary
-----------------
To evaluate, in a controlled setting, the early safety and effectiveness of the Penumbra/Indigo aspiration thrombectomy Systems (San Francisco, California), and to define optimal technique for the use of these systems in patients with confirmed peripheral acute occlusions.

Official Title
-----------------
Indian Registry (The INDigo System in Acute Lower Limb malperfusioN)

Conditions
-----------------
Acute Ischemia of Lower Limb

Intervention / Treatment
-----------------
* Device: Indigo Mechanical Thrombectomy System


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients will be selected based on the investigator's assessment and evaluation of the underlying disease. The patient's medical condition should be stable, with no underlying medical condition that would prevent them from performing the required testing or from completing the study. Patients should be geographically stable, willing and able to cooperate in this clinical study, and remain available for mid term follow-up. Patients who do not wish to participate in this study can obtain any other standard commercially available device therapy. Refusal to participate in this study will in no way affect their care at the institution. Inclusion Criteria Patient presenting with an acute occlusion of lower limb arteries (thrombosis no longer than 14 days) Patient presenting a score from I to IIb following Rutherford classification for acute limb ischemia Patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study Patient is >18 years old Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study Patient is eligible for treatment with the Indigo System (Penumbra) Exclusion Criteria Estimated time of intraluminal thrombus > 14 days Patients refusing treatment Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated Patients with a history of prior life-threatening contrast medium reaction Life expectancy of less than six months Any patient considered to be hemodynamically unstable at onset of procedure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Treatment by Indigo mechanical thrombectomy system<br>Acute or Chronic clot: if chronic (> 14 days) no intervention given via Indigo | Device: Indigo Mechanical Thrombectomy System<br>* Removal of acute clot (< 14 days) from the artery causing lower limb ischemia, using the Indigo System by Penumbra<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Technical success of the thromboaspiration with the Indigo system. | The primary endpoint of the study is the technical success of the thromboaspiration with the Indigo system. Assessment of vessel patency will be recorded using the Thrombolysis in Myocardial Infarction (TIMI) score classifications both before and after use of the device. | At intra-procedural completion angiography | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical success at 1 month follow-up. | Clinical success at follow-up is defined as an improvement of Rutherford classification at 1-month follow-up of one class or more as compared to the pre-procedure Rutherford classification. | 1 month | 
| Safety Rate at discharge: Serious adverse event. | Safety rate at discharge, defined as absence of any serious adverse events (SAE). A SAE is defined as any clinical event that is fatal, life-threatening, or judged to be severe by the investigator; resulted in persistent or significant disability. | 1 month | 
| Primary Patency | Primary patency at 1 month. Primary patency is defined as a target lesion without a hemodynamically significant stenosis/reocclusion on duplex ultrasound (>50%,) and without target lesion reintervention (TLR) within 1 month. | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute ischemia, Lower Limb